Adlai Nortye Ltd.

ANL

Explore Our Financial Data > Companies > Adlai Nortye Ltd.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ANL
CIK	0001944552
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ, 08902
Website	www.adlainortye.com
Phone	848-230-7430
CEO	Yang Lu
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$5.23 million
Pre-Tax Income	$-35.53 million
Net Income	$-35.53 million
Net Income to Common	$-35.53 million
EPS	N/A

View All

Balance Sheet

Cash	$8.06 million
Assets	$34.43 million
Liabilities	$42.76 million
Common Equity	$-8.32 million
Liabilities & Equity	$34.43 million

View All

Cash Flow Statement

Net Income	$-35.53 million
Cash From Operating Activities	$-33.45 million
Cash From Investing Activities	$-15.58 million
Cash From Financing Activities	$-3.81 million
Change in Cash	$-52.84 million

View All

Calculations

NOPAT	$-24.83 million
EBITDA	$-34.11 million
Price to Earnings	N/A
Price to Book	N/A
ROE	-414.01%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-st

Article Link

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage

Article Link

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.

Article Link

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology. “We are pleased to welcome Chris to Adl

Article Link

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Why the AN4035 trial move matters for Adlai Nortye Group stock Adlai Nortye Group (NasdaqGM:ANL) has just dosed the first patient in its global Phase I trial for AN4035 and secured a Study May Proceed letter from the FDA, clearing expansion into the United States. The fresh AN4035 milestone comes after a strong run in Adlai Nortye Group’s stock, with a very large year-to-date share price return and a 1-year total shareholder return of about 8x. Recent 30-day and 90-day share price returns of...

Article Link